Mechelen, Belgium; 15 June 2023, 22:01 CET; regulated information - Galapagos NV
(Euronext & NASDAQ: GLPG) today announced the appointment of Thad Huston as
Chief Financial Officer (CFO) and Chief Operating Officer (COO) as per 1 July
2023. Mr. Huston will be a member of the Executive Committee of Galapagos and
will join Galapagos from Kite, a Gilead Company (NASDAQ: GILD). He brings 30
years of global finance and operational experience in healthcare with an
excellent track record of driving business transformation and innovation.
"On behalf of the Board of Directors and management of Galapagos, I extend a
warm welcome to Thad. Thad is a widely recognized leader with a strong
international network. Having spent three decades in the healthcare sector, he
brings with him a wealth of experience and deep financial and operational know-
how," said Dr. Paul Stoffels(1), CEO and Chairman of Galapagos. "We are
convinced that Thad's strategic and operational expertise, including in cell
therapy, is an excellent fit for our company as we continue to execute on our
R&D and business development strategy in our focus areas of immunology and
oncology."
Thad Huston is currently Global Head of Finance and Corporate Operations at
Kite, the global leader in cell therapy. Before Kite, Thad served as CFO of
LivaNova (NASDAQ: LIVN), a publicly listed medical devices company focused on
neuromodulation with presence in more than 100 countries. Prior to that role, he
spent over 25 years at Johnson & Johnson (J&J) (NYSE: JNJ) where he held senior
financial roles at various J&J locations in the
US, China, Belgium, Russia, and Hungary. During his tenure at J&J, he helped
establish the R&D innovation model and played a key role in accelerating the
product pipeline through focused growth strategies, investments in innovation,
business development and streamlined productivity.
"I am very excited to join Galapagos and to work with Paul and the team to
realize the company's full potential," added Thad Huston. "With its growing
pipeline in oncology and immunology, a European commercial infrastructure and a
robust balance sheet, I strongly believe that Galapagos has the fundamentals in
place to deliver on its mission to transform the lives of patients across the
globe, while creating value for its stakeholders."
This press release contains inside information within the meaning of Regulation
(EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014
on market abuse (market abuse regulation).
About Galapagos
Galapagos is a fully integrated biotechnology company united around a single
purpose: to transform patient outcomes through life-changing science
and innovation for more years of life and quality of life. We focus on the key
therapeutic areas of immunology and oncology, where we have developed a deep
scientific expertise in multiple drug modalities, including small molecules and
cell therapies. Our portfolio comprises discovery through to commercialized
programs and our first medicine for rheumatoid arthritis and ulcerative colitis
is available in Europe and Japan. For additional information, please
visit www.glpg.com (http://www.glpg.com/) or follow us on LinkedIn
(https://www.globenewswire.com/Tracker?data=ezxJkwSFR72hjpmLV87_rCWHmXiEkJdYmJZA
mM2ogtGbwOFtqfgHUBEEFGXHaFo83cvmiDFpg4AEmLKK78dHsjgGmCaeMvJ36E2Ayj-
ezOHnYHIaUIAZlc1A0XmbkMKzClCPc7hEiPOvByRSfbsFQunjB9Mw2v2EXH653ri5widmmTRkrkre_FA
Y2bZEDq-VJC9NEfuFyUPT0A29gI-
p13O_hFuDoS9sZUqcxgX6JcnrwMRT63EZMXbky2R5cA0wPn3z0x5aqDb4BY1NBSLYewJzDF3OBhrblWA
hgWvClWvZVrI_FoJWrVp-KlQ91FztQeQrUb9bss1A59BpNVDQLuE5mW2kAbA-
lwKqe56rVnXPtYPdq2b7-
8gnY3_3Im5KOPoLjl9xR5WeSc7rBZ76O5rrd1J3p2c292_9pUauVIxKkxhwE-
JQpKN6DSA1L4EqK7XtUTAcJQw4l_jzaSKIBTNyxJDd3e4eo2KiYIn-zFqPBOqvSMIdJFYNDxr-
H4U5IzD_KAqNRLjM6QQ9ixbssNjrCtLrmd4DpeQX9EbGdypFqCboHKE2YNXgRYNzIppmf8br_LKU1eD5
fxZVMpzuFeeSpopW66cNapQM_k8YfhKBPvgRnuj06a3LGeWH2OzNwLZ4junayWghclaIgY6KtVwEXh_l
5jYtP8eUoBnsqgr5UVGRGLFPa8ZKbe20xzl_jPWftZaxCkIq8_iH2cs-oQ==) or Twitter
(https://www.globenewswire.com/Tracker?data=R498b57aPdjPPnpO80BvL5Dj20Y9F_la0Ss0
CxwYvDH8H56pXknrj_Md3DIU2_LoG9WbkunFYQ_mBbwylanRgyQA1xrVx2NE6O1MbiqeORMvKGc2yYso
qKnVQr8_LQyhOSXFgM01nLkEXHAmRH8ve5jiRThZeVD-
P95cNmE1Z6RNkXNiUEGyY89pziVjbXAGgpU0tDva-Dv9o0z80p58C-
J8fDfOMQFBY6HcSmpNclzdUyWHgdjP2ENXamg-LwvJSqCeZ1Xy4ZJA_krwQER-
lsJpuwUsO1wkBzcN7E_cPQVOvlNQ8OxyKaGqRpkxyEO8gLj9jBKPFlQ4LE1nQ2vhyjmst-
aJv2XFFvFrqvaXR5dW_4_IwYUu8MWzJa9m23v2w_zWgLD9PI30j_xCxTrugA7sOiEvHw9ALHiEjgu61T
Le-oLdpFcjekviEdsXkG-
leAzl17cVoc9YQo_yTB9FT_35A0hEm8QyAbcp5OtmFMnfLPQIRlCY5BcjeR8-
GeV13IvKT7yE8JHas4wlj4SSnE3pckT1EXou1yle_rmshbKTuIWS8VLedeuzxQT_TxgUMl5CbUmYtCRf
yXpUoqzPtfXywFbemSlAQt_7oPCcbm082dOus_7a-
0GpaCdE2tatiaUScKEYInlUFYco8vSRm1VUREUk3b9UhM9edL9C3BN0PU2f9-0n1GToRrvrW1htdBJg3
Eafs7tjYALDBZp9sQ==).
Contacts

  Media relations contact                    Investor relations contact
  Marieke Vermeersch                         Sofie Van Gijsel
  +32 479 490 603                            +1 781 296 1143
  media@glpg.com (mailto:media@glpg.com)
                                             Sandra Cauwenberghs
                                             +32 495 58 46 63
                                             ir@glpg.com (mailto:ir@glpg.com)

Forward-looking statements
This press release includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended. These statements
are often, but are not always, made through the use of words or phrases such as
"ongoing," "will," and "may" as well similar expressions. Forward-looking
statements contained herein include, but are not limited to, statements
regarding the announced leadership transition and changes in our Executive
Committee and key personnel. These forward-looking statements are subject to
risks, uncertainties and other factors that could cause actual results to di?er
materially from those referred to in the forward-looking statements and,
therefore, the reader should not place undue reliance on them. These risks,
uncertainties and other factors include, without limitation, the possibility
that Galapagos will encounter challenges retaining or attracting talent, that
our leadership transition may be disruptive to our business operations, risks
related to our ability to effectively transfer knowledge during this period of
transition, and those risks and uncertainties identified in our Annual Report on
Form 20-F for the year ended 31 December 2022 and our subsequent filings with
the SEC. The forward-looking statements contained herein are based on
management's current expectations and beliefs and speak only as of the date
hereof, and Galapagos makes no commitment to update or publicly release any
revisions to forward-looking statements in order to reflect new information
or subsequent events, circumstances or changes in expectations, unless
specifically required by law or regulation.
--------------------------------------------------------------------------------
(1) Throughout this press release, 'Dr. Paul Stoffels' should be read as 'Dr. Paul Stoffels, acting via Stoffels IMC BV'
Â